Research desk · NGEN · Nasdaq

SEC financials, peer compare, and chart. Scores open the matching desk. Research only — not advice.

NERVGEN PHARMA CORP. · Pharmaceutical Preparations

NERVGEN PHARMA CORP. financial statements, chart, and peer compare from SEC filings.

NERVGEN PHARMA CORP. (NGEN) discovers, develops, or markets pharmaceutical products.

Market cap
$148.15M
P/E
-3.05
Op. margin
—
Profit margin
—
FCF margin
—
ROE
-1,268.86%

Related Health Care stocks: CYDY stock financials · ALZN stock financials · PMCB stock financials · CAPR stock financials · STOK stock financials

See Health Care moving on the anomaly desk

misprise.com
Watch / incomplete (<60) FY2025 Updated August 23, 2026 11:49 am ← Screener
Primary research · 02

NGEN financial statements

Each Compare name is its own block of years. Filing lines are SEC reports; P/E and price sit on that name’s TTM column only.

Primary research · 03

NGEN stock peer compare

Each bar is that name’s percent vs its last TTM, on one zero line. Zero is unchanged. This ticker is the black bar.

Focus chart

Zero is unchanged vs last TTM. Every name is a percent for the metric you pick.

Supporting · 04

NGEN stock peer headlines

Yahoo Finance RSS for NGEN and the names in Compare.

Ticker Date Headline
Loading headlines…
Supporting · 05

NGEN stock price chart

Overlays follow the Compare table.

Chart loads when you scroll here
Supporting · 06

NGEN stock — research snapshot

Screen strengths and watchouts for NGEN stock from the latest Misprise snapshot.

Strengths

  • No standout screen strengths in this snapshot — check the statements for the full picture.

Watchouts

  • ROA -190.1% — muted asset returns.
  • ROE -1,268.9% — soft equity returns.
  • Recent EPS growth -69.4% — earnings momentum is weak.
  • Rev CAGR 5Y —
  • Rev CAGR 3Y —
  • EPS CAGR 5Y —
  • EPS CAGR 3Y —
  • FCF CAGR 5Y —
  • FCF CAGR 3Y —
Supporting · 07

NGEN stock FAQs

Short answers for NGEN stock — statements, sector, and how this page is meant to be used.

What is NGEN stock?

NERVGEN PHARMA CORP. (NGEN) discovers, develops, or markets pharmaceutical products. NGEN stock sits in Health Care (Pharmaceutical Preparations), listed on Nasdaq.

Where can I find NERVGEN PHARMA CORP. financial statements?

NERVGEN PHARMA CORP. financial statements — income statement, balance sheet, and cash flow — are on this NGEN stock page, parsed from SEC 10-K and 10-Q filings. Use Annual or Quarterly, then the statement tabs. Research only.

What happened to NGEN stock?

This page is a research snapshot of NERVGEN PHARMA CORP. (NGEN) from the latest SEC filings in the Misprise database as of FY2025. It is not a news feed or a delisting notice. Open the financial statements, chart, and peer compare below, then read the filings. Research only — not financial advice.

Does this page show the NGEN stock price?

The live chart on this NGEN stock page is the same TradingView chart as the screener. Statement tables use SEC filings. Any price or multiple on the TTM column is a market snapshot from the last seed, not a real-time quote. Research only.

What sector is NGEN stock in?

NERVGEN PHARMA CORP. is classified in Pharmaceutical Preparations, inside the Health Care sector, and trades on Nasdaq. This page is a research snapshot, not a full company profile.

How do I read NGEN financial statements?

Start with this ticker’s block (TTM, then its fiscal years or quarters). Each Compare name is a separate block of its own periods — not mixed by year. A blank is a period we do not have, not a zero. Research only — not a buy or sell.

Where does the NGEN statement data come from?

Income, balance sheet, and cash-flow lines are parsed from SEC company filings (10-K / 10-Q and 20-F). TTM is the last four reported quarters added together, not a separate filing. P/E, forward P/E, price, and market cap are a market quote at last seed — trailing P/E from the quote when available, otherwise last price divided by TTM EPS. They are not 10-K line items and appear on the TTM column only. Research only — not financial advice.

Where can I find the NGEN income statement, balance sheet, and cash flow?

On this NGEN stock page, open Financial statements and use the Income, Balance sheet, and Cash flow tabs. Growth and valuation sit under More. Filing figures are from SEC reports; valuation multiples are the market snapshot described above.

What is the Misprise Score for NGEN stock?

NGEN stock currently scores 0/100 (Watch / incomplete (<60)). NERVGEN PHARMA CORP. scores weaker or incomplete on durable growth/quality inputs — leverage, coverage, and recent results deserve extra scrutiny. The score is a screen of quality, growth, and balance-sheet inputs — not a price target. Compare it in the Misprise screener; it is not a separate score page.

How is the NGEN comparison winner decided?

Lead and Tie follow the number printed on each factor row, not a blended category score. Growth, quality, score, current ratio, and coverage: the higher figure leads. Value multiples (P/E, PEG, P/B, P/S) and debt ratios: the lower figure leads. Tie appears only when those printed numbers match. The header winner is whoever takes more of those five rows. CAGR uses the 5-year horizon and drops to 3-year only when both names report it. Research only — not a buy or sell.

What is the Anomaly Score on this NGEN page?

Anomaly Score is how unusual a filing pattern is versus this company’s own history and its industry — not the same as Misprise Score. A high anomaly with a weak Misprise Score is often a noisy name. Open the anomaly detector to see the flag. Research only — not financial advice.

What does the green grant dot mean on NGEN stock?

A green circle next to the title means this ticker appears in the Misprise grants calendar with a recent federal award (USASpending / SAM). Tap the dot for date, agency, and amount when available. It is a research flag only — not a buy or sell signal.

Is NGEN stock a buy?

No recommendation either way. This NGEN stock page organizes statements, ratios, and peers so you can do your own work. It is educational only — not advice to buy or sell NERVGEN PHARMA CORP..